| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
102,230,000 |
| Market
Cap: |
10.87(M) |
| Last
Volume: |
10,264,973 |
Avg
Vol: |
10,236,952 |
| 52
Week Range: |
$0.1063 - $1.64 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Seelos Therapeutics is a clinical-stage biopharmaceutical company focused on the development of products that address unmet needs in Central Nervous System disorders and other disorders. Co.'s primary programs are SLS-002 for the potential treatment of Acute Suicidal Ideation and Behavior in patients with Major Depressive Disorder and SLS-005 for the potential treatment of Amyotrophic Lateral Sclerosis and Spinocerebellar Ataxia. Co. is also developing several preclinical programs, including SLS-004, SLS-006, and SLS-007 for the potential treatment of Parkinson's Disease, SLS-010 in narcolepsy and related disorders, and SLS-012, an injectable therapy for post-operative pain management.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
158,757 |
158,757 |
| Total Buy Value |
$0 |
$0 |
$200,222 |
$200,222 |
| Total People Bought |
0 |
0 |
2 |
2 |
| Total Buy Transactions |
0 |
0 |
2 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dorsey Brian |
SVP, Chief Development Officer |
• – – |
2016-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
250,000 |
301,891 |
|
- |
|
| Dorsey Brian |
SVP, Chief Development Officer |
• – – |
2016-04-25 |
4/A |
A |
$0.00 |
$0 |
D/D |
0 |
51,891 |
|
- |
|
| Morton Neil |
SVP, Chief Business Officer |
• – – |
2016-04-25 |
4/A |
A |
$0.00 |
$0 |
D/D |
0 |
29,496 |
|
- |
|
| Bovenizer Catherine |
VP Finance & CAO |
• – – |
2016-04-25 |
4/A |
A |
$0.00 |
$0 |
D/D |
0 |
34,594 |
|
- |
|
| Morton Neil |
SVP, Chief Business Officer |
• – – |
2016-04-25 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
129,496 |
|
- |
|
| Pascoe Richard W |
CEO & Secretary |
• • – |
2016-04-25 |
4 |
A |
$0.00 |
$0 |
D/D |
350,000 |
476,778 |
|
- |
|
| Dorsey Brian |
SVP, Chief Development Officer |
• – – |
2016-04-25 |
4 |
A |
$0.00 |
$0 |
D/D |
250,000 |
301,891 |
|
- |
|
| Bovenizer Catherine |
VP Finance & CAO |
• – – |
2016-04-25 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
84,594 |
|
- |
|
| Smith Sandford D |
Director |
– • – |
2016-04-05 |
4 |
A |
$0.58 |
$2,813 |
D/D |
4,850 |
31,350 |
|
- |
|
| Maier Paul V |
Director |
– • – |
2016-04-05 |
4 |
A |
$0.58 |
$3,625 |
D/D |
6,250 |
6,250 |
|
- |
|
| Xanthopoulos Kleanthis G |
Director |
– • – |
2016-04-05 |
4 |
A |
$0.58 |
$5,000 |
I/I |
8,621 |
64,356 |
|
- |
|
| Ray Rusty |
Director |
– • – |
2016-04-05 |
4 |
A |
$0.58 |
$3,438 |
D/D |
5,927 |
38,279 |
|
- |
|
| Wierenga Wendall D |
Director |
– • – |
2016-04-05 |
4 |
A |
$0.58 |
$2,813 |
I/I |
4,850 |
24,850 |
|
- |
|
| Morton Neil |
SVP, Chief Business OfficerOff |
• – – |
2016-04-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
29,496 |
|
- |
|
| Pascoe Richard W |
CEO & Secretary |
• • – |
2016-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
79,778 |
126,778 |
|
- |
|
| Bovenizer Catherine |
VP Finance & CAO |
• – – |
2016-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
34,594 |
34,594 |
|
- |
|
| Troupin Barbara |
SVP, Chief Medical Officer |
• – – |
2016-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
43,918 |
43,918 |
|
- |
|
| Dorsey Brian |
SVP, Chief Development Officer |
• – – |
2016-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
41,891 |
51,891 |
|
- |
|
| Sarissa Capital Offshore Master Fund Lp |
10% Owner |
– – • |
2016-03-03 |
4 |
B |
$0.88 |
$5,850,001 |
I/I |
6,647,728 |
14,479,053 |
1.5 |
- |
|
| Sarissa Capital Offshore Master Fund Lp |
10% Owner |
– – • |
2016-01-12 |
4 |
B |
$0.88 |
$1,150,001 |
I/I |
1,306,819 |
7,831,324 |
1.5 |
- |
|
| Sarissa Capital Domestic Fund Lp |
10% Owner |
– – • |
2015-02-13 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
6,524,505 |
|
- |
|
| Dorsey Brian |
Chief Development Officer |
• – – |
2014-12-29 |
4 |
B |
$1.05 |
$10,481 |
D/D |
10,000 |
10,000 |
2.74 |
- |
|
| Pascoe Richard W |
Chief Executive Officer |
• • – |
2014-12-22 |
4 |
B |
$1.02 |
$10,217 |
D/D |
10,000 |
47,000 |
2.81 |
- |
|
| Smith Sandford D |
Director |
– • – |
2014-10-23 |
4 |
B |
$1.59 |
$28,998 |
D/D |
18,200 |
26,500 |
2.39 |
- |
|
| Smith Sandford D |
Director |
– • – |
2014-10-22 |
4 |
B |
$1.52 |
$12,651 |
D/D |
8,300 |
8,300 |
2.39 |
- |
|
78 Records found
|
|
Page 3 of 4 |
|
|
